Ruckhofer J, Stoiber J, Alzner E, Grabner G
Landesklinik für Augenheilkunde und Optometrie, Landeskliniken Salzburg, Austria.
J Cataract Refract Surg. 2001 Feb;27(2):277-86. doi: 10.1016/s0886-3350(00)00749-5.
To assess the efficacy, predictability, stability, and safety of correcting myopia with intrastromal corneal ring segments (ICRS, KeraVision, Inc.).
Twelve European investigational sites.
Patients with myopia of -1.0 to -6.0 diopters (D) and best spectacle-corrected visual acuity (BSCVA) of 20/20 or better (except in 3 eyes) were assigned to receive 1 of 5 ICRS thicknesses (0.25, 0.30, 0.35, 0.40, or 0.45 mm). Efficacy was assessed by postoperative uncorrected visual acuity (UCVA), predictability of refractive outcome (deviation from predicted cycloplegic refraction spherical equivalent), and stability of refractive effect (manifest refraction spherical equivalent [MRSE]). Safety was assessed by maintenance or loss of preoperative BSCVA and induced manifest refraction cylinder. Measurements were made preoperatively and 1 and 7 days and 1, 2, 3, 6, and 12 months postoperatively.
One hundred fifty-nine ICRSs were implanted in the eyes of 107 patients (52 patients had bilateral implantation). Preoperatively, UCVA was worse than 20/40 in 98% of eyes (155/159); 12 months postoperatively, it was 20/20 or better in 63% of eyes (83/132) and 20/40 or better in 96% (127/132). Predicted refractive corrections for each ICRS thickness generally correlated with achieved corrections. At 12 months postoperatively, 90% of eyes (124/138) were within +/-1.00 D of plano (MRSE). Two or more lines of BSCVA were lost in 6% of eyes (8/135); all 8 eyes had BSCVAs of 20/25 or better.
The ICRS safely, effectively, and predictably reduced or eliminated low to moderate myopia. Refractive correction was stable through the 12 month follow-up.
评估使用基质内角膜环片(ICRS,KeraVision公司)矫正近视的疗效、可预测性、稳定性及安全性。
12个欧洲研究地点。
将近视度数为-1.0至-6.0屈光度(D)且最佳矫正视力(BSCVA)为20/20或更佳(3只眼除外)的患者分配接受5种ICRS厚度(0.25、0.30、0.35、0.40或0.45毫米)中的一种。通过术后裸眼视力(UCVA)、屈光结果的可预测性(与预测的睫状肌麻痹验光球镜等效度的偏差)以及屈光效果的稳定性(显验光球镜等效度[MRSE])评估疗效。通过术前BSCVA的维持或丧失以及诱导的显验光柱镜评估安全性。术前以及术后1天、7天、1个月、2个月、3个月、6个月和12个月进行测量。
107例患者(52例患者为双眼植入)的眼内植入了159片ICRS。术前,98%的眼(155/159)的UCVA低于20/40;术后12个月,63%的眼(83/132)的UCVA为20/20或更佳,96%(127/132)为20/40或更佳。每种ICRS厚度的预测屈光矫正通常与实际矫正相关。术后12个月,90%的眼(124/138)的MRSE在±1.00 D的平光范围内。6%的眼(8/135)丧失了两行或更多行的BSCVA;所有8只眼的BSCVA均为20/25或更佳。
ICRS安全、有效且可预测地降低或消除了低度至中度近视。在12个月的随访期间屈光矫正稳定。